FLUZONE HIGH-DOSE SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [SIN17611P]
Active ingredients: A/DARWIN/9/2021 (H3N2)-LIKE STRAIN | A/VICTORIA/4897/2022 (H1N1)PDM-09-LIKE STRAIN | B/AUSTRIA/1359417/2021-LIKE STRAIN
Product Info
FLUZONE HIGH-DOSE SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
[SIN17611P]
Product information
Active Ingredient and Strength | A/DARWIN/9/2021 (H3N2)-LIKE STRAIN - 60 MCG/0.5 ML |
Dosage Form | INJECTION, SUSPENSION |
Manufacturer and Country | SANOFI VACCINES US INC. - UNITED STATES |
Registration Number | SIN17611P |
Licence Holder | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07BB02 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
Fluzone High-Dose is indicated for active immunisation in adults 65 years of age and older for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine.
The use of Fluzone High-Dose should be based in accordance with official recommendations on vaccination against influenza.
Dosing
4.2 Posology and method of administration
Posology
In adults 65 years of age and older: one dose of 0.5 ml.
Paediatric population
The safety and effectiveness of Fluzone High-Dose in children less than 18 years of age have not been established.
Method of administration
The route of administration for this vaccine is intramuscular.
The recommended site for intramuscular injection is the deltoid region. The vaccine should not be injected into the gluteal region, or into areas where there may be a major nerve trunk.
For instructions on preparation of the medicinal product before administration, see Section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in Section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins) and formaldehyde.
